Showing posts with label test1. Show all posts
Showing posts with label test1. Show all posts

Wednesday, March 23, 2011

Bang

Bang Bang

Tuesday, March 22, 2011

test Light Box

fhjshdfhsjdkgfih
gdfgdf

Test No iamge(PIC)

Monday, March 21, 2011

Test 19

Test 18

Test

Test 17

Test 17 No image

Test 16


Test 14 asdghagfhjsdgfjsdghjsggkfjsdgsdjgfkdjfgioerughmndmfnbkldfnkjbnghdfjghkjdfhgkdfhgkdhkjgndfkjnbdkbnkdfnbmkfdnbkgfjbkdkjhgfdkjghfjhgfkjhgkjfdgdf bkfjdkbnkjgfngfkb kjf bkfg bkf bkfg kb dfkb

bdfbdfb

Test ZZ : 2346523745237452715721251258689436583658354368368536856384538256t38465tr8jerggdfvh4huerihgv94erhg4uh9yerw8ghwerhvjwhhei

Saturday, March 19, 2011

Test 13 sdhgdfhgkdlhfgkdhlkghdslgfsdkghlsdfg

tewfjsd;nfglsdkgnlkdnfvblgdfb
h
gfh

fghf
gh
gfh
fg
h
gf
b
gf
nbgf
n

Test 12 No image

no image
sdsfjsdlj
sdgsl;dg
sg
dfg
df
g
fd
hbg
h
gfj
gf
j
h
jh
gj
hglfkghl';gfj

ghnjgfjgf

test 11 : General propleam about blog.


Topics 11 test about related post

test 10

test 9

test 8

tes8


Monday, March 14, 2011

tertywei

Test 33


Deferiprone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Deferiprone
Systematic (IUPAC) name
3-hydroxy-1,2-dimethylpyridin-4(1H)-one
Identifiers
CAS number 30652-11-0
ATC code V03AC02
PubChem CID 2972
ChemSpider 2866 YesY
KEGG D07416 YesY
ChEMBL CHEMBL70927 YesY
Chemical data
Formula C7H9NO2 
Mol. mass 139.152 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Metabolism Glucuronidation
Half-life 2 to 3 hours
Excretion Renal (75 to 90% in 24 hours)
Therapeutic considerations
Licence data EMA:Link
Pregnancy cat.  ?
Legal status  ?
Routes Oral
 YesY(what is this?)  (verify)
Deferiprone (tradenames include Ferriprox) is an oral drug that chelates iron and is used to treat thalassaemia major.[1]
It is currently licensed for use in Europe and Asia, but not in Canada and the United States.[1][2]
Deferiprone is in clinical trials in the United States to treat Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; the trials are being conducted by the biotech company, Cormedix.[3]

[edit] Controversy

Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and pharmaceutical giant Apotex, that started in 1996.[4] Dr. Olivieri's data suggested that deferiprone leads to progressive hepatic fibrosis, a finding which is in dispute.[5][6]